Search Results for "Pacira Orbimed"
Original Source: Pacira Pharmaceuticals, Inc.
Pacira Pharmaceuticals, Inc. is an acute care specialty pharmaceutical company founded in March, 2007 through the acquisition of the former SkyePharma PLC injectable business, for which an experienced management team was assembled to address the needs of the acute care market. The company's most advanced product, EXPAREL(TM) (DepoBupivacaine), a bupivacaine-based product intended to deliver post operative pain relief by infiltration, is in late Phase III clinical development for postsurgical pain. EXPAREL(T...
Matching Channels
None
Matching News
Pacira Raises Wall Street Expectations of a New Blockbuster Painkiller
The last time Xconomy checked in with Pacira Pharmaceuticals (NASDAQ: PCRX), in early 2009, the company was laying off a third of its workforce in the wake of a disappointing clinical trial of Exparel...
Pacira Insiders Sold $25 Million Last Week - But Why ?
By Richard Pearson:Last week I published an article noting several sell signals which were emerging at Pacira Pharmaceuticals (PCRX), which was closing in on a triple since 2012. In just the past few...
Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that David Stack, president and chief executive officer of Pacira Pharmaceuticals, is scheduled to present at th...
Pacira Pharmaceuticals, Inc. to Present at the UBS Global Life Sciences Conference
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that David Stack, president and chief executive officer of Pacira Pharmaceuticals, is scheduled to present at th...
Pacira Pharmaceuticals, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that David Stack, president and chief executive officer of Pacira Pharmaceuticals, is scheduled to present at th...
Convertible notes offering nets $105.7mm for [Pacira]
Drug delivery company [Pacira Pharmaceuticals Inc.] has netted $105.7mm by selling to institutional investors 3.25% six-year senior notes that convert into cash up to the principal amount; anything in...
Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that David Stack, president and chief executive officer of Pacira Pharmaceuticals, is scheduled to present at th...
Pacira Pharmaceuticals, Inc. to Present at the Cowen and Company 33rd Annual Health Care Conference
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that David Stack, president and chief executive officer of Pacira Pharmaceuticals, is scheduled to present at th...
Matching PubMed Articles
Considerations in Developing a Target Product Profile for Parenteral Pharmaceutical Products.
A target product profile (TPP) describes how a product will be utilized by the end user. A systematically developed TPP can ensure alignment of objectives across company departments, accelerate develo...
Objective: DepoFoam bupivacaine (DB) is in development for prolonged postoperative analgesia. Studies were conducted to evaluate the potential local and systemic toxicity and any effect on wound heali...
Development of cytarabine prodrugs and delivery systems for leukemia treatment.
Importance of the field: Cytarabine is a polar nucleoside drug used for the treatment of myeloid leukemia and non-Hodgkin's lymphoma. The drug has a short plasma half-life, low stability and limited b...
